The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 29, 2026
Filed:
May. 05, 2022
Biogen MA Inc., Cambridge, MA (US);
C4 Therapeutics, Inc., Watertown, MA (US);
Kevin M. Guckian, Northborough, MA (US);
Eric Stefan, Watertown, MA (US);
Corey Don Anderson, Brighton, MA (US);
Jae Young Ahn, Somerville, MA (US);
Morgan Welzel O'shea, Waltham, MA (US);
Jeremy L Yap, Sudbury, MA (US);
Xinpeng Cheng, Watertown, MA (US);
Brian T. Hopkins, Newton, MA (US);
Isaac Marx, Arlington, MA (US);
Marta Nevalainen, Holliston, MA (US);
BIOGEN MA INC., Cambridge, MA (US);
Abstract
This disclosure relates to compounds of Formula (A): BTK-L-DSM (A) or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches BTK to DSM, and BTK is a Btk binding moiety represented by Formula (I) or Formula (II) that is covalently attached to linker L: in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of Btk proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of Btk proteins. The present disclosure also provides methods of treating disorders responsive to modulation of Btk activity and/or degradation of Btk with at least one compound described herein.